1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: VC Mega-Rounds Make A Comeback In March

Several $100m-Plus Financings After Early 2023 Drought

 
• By Mandy Jackson

Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.

Finance Watch Private Company
• Source: Shutterstock

After what seemed like a relatively quiet stretch for venture capital mega-rounds of $100m or more, the pace of large VC financings has picked up in March with five big rounds announced already this month, led by a $200m series A for CARGO Therapeutics, Inc., which launched on 1 March to develop next-generation chimeric antigen receptor T-cell (CAR-T) therapies, including a Phase II-ready asset.

Venture capital investors raised billions of dollars during the past few years for biopharma opportunities, but many slowed the pace...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Jefferies Conference 2025: Five Themes To Follow

 
• By Andrew McConaghie

The investor event will bring deal-hungry big pharma and biotech execs together but input from the FDA’s unsettled leadership will be missing this year.

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

Finance Watch: Public Biopharma Company Financings Surged Globally In Q3

 
• By Mandy Jackson

Public Company Financings: Biomedtracker’s third quarter report shows a big jump from Q2 in follow-on offerings, private placements and debt. Also, Evommune brings the US biopharma IPO tally for 2025 to a dozen and Merck’s Blackstone deal gives it $700m to develop a key ADC asset.

Finance Watch: Braveheart Launches With $185m To Start Late-Stage Trials

 
• By Mandy Jackson

Private Company Edition: Braveheart Bio licensed its selective cardiac myosin inhibitor from Hengrui. Also, Arena BioWorks shuts down after raising $500m in 2024, GHO Capital closed a €2.5bn ($2.9bn) private equity fund and new cash brings Tubulis’s series C to €344m ($401m).

More from Business

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.

Finance Watch: Public Biopharma Company Financings Surged Globally In Q3

 
• By Mandy Jackson

Public Company Financings: Biomedtracker’s third quarter report shows a big jump from Q2 in follow-on offerings, private placements and debt. Also, Evommune brings the US biopharma IPO tally for 2025 to a dozen and Merck’s Blackstone deal gives it $700m to develop a key ADC asset.